The global non-opioid pain patches market size was valued at USD 732.6 million in 2018 and is expected to grow at a compound annual growth rate (CAGR) of4.6% from 2019 to 2026.Global rise in chronic and acute pain related disorders and various benefits associated with non-opioid pain patches over conventional medications are some of the major factors driving the market growth.
The global opioid epidemic has escalated at an alarming rate, owing to which several countries have opted for other alternatives for the management of pain. In November 2017, opioid crisis was declared as a national emergency indicating the impact of opioid addiction in the U.S. According to data from National Institute of Drug Abuse, an estimated 90 Americans die of opioid overdose every day.
The Centers for Disease Control and Prevention estimates that the economic burden brought upon the country because of opioid misuse amounts to USD 78.5 billion every year. These costs include those incurred for healthcare expenditure, addiction treatment, loss of productivity, and criminal justice involvement. These facts are indicative of the growing need to curb this addiction. Thus, demand for other alternatives that are safe has increased, boosting market growth.
Pain and related disorders are increasing at a rapid rate globally owing to changes in lifestyle, lack of physical activity, and growing number of surgical procedures. Chronic and acute pain affects more Americans than diabetes, cancer, and heart diseases combined, according to the U.S. Department of Health and Human Services (HHS). HHS also reported that pain is the most common reason for visits to healthcare facilities, which makes it the foremost cause of disability in patients, thereby contributing largely to healthcare costs. The aforementioned factors are encouraging the discovery of safe and effective management options such as non-opioid pain patches, thus boosting their market growth.
Based on patch type, the non-opioid pain patch market is segmented into lidocaine, diclofenac, methyl salicylate, capsaicin, and ketoprofen patches. These are used to alleviate pain and provide efficient drug delivery for a prolonged period. As they bypass the first pass metabolism, they are more efficient in drug delivery and prohibit users from becoming addicted to the drug.
In comparison to opioids that exhibit a wide range of adverse effects such as nausea, vomiting, respiratory depression, constipation, androgen deficiency, tolerance, and physical dependency, these patches provide users with efficient treatment and management of chronic and acute pain. Drug dependence and misuse is significantly reduced with the usage of these patches, and this is expected to increase their demand and propel the market.
Lidocaine patches are one of the most commonly available non-opioid patches for the treatment of chronic and acute pain. Owing to their safety profile and proven efficacy, lidocaine patches have been recommended as a first-line therapy for the treatment of neuropathic pain in older patients as well as those suffering from shingles, and this is expected to boost market growth during the forecast period.
Compared to oral diclofenac tablets, these patches are preferred by patients due to their once-a-day application and enhanced efficacy. Flector patch developed by IBSA Institut Biochimique SA is an example of a diclofenac patch that aids in the management of acute and chronic pain. The product is licensed by Alpharmca Pharmaceuticals LLC which operates as a subsidiary Pfizer, Inc.
Methyl salicylate patches held a considerable share in the market owing to easy availability and consistent usage for the treatment of acute pain. PanaFlex Patch is a methyl salicylate patch developed by GSK, which aids in the management of aching and tired muscles. In addition, the product can be used for the temporary treatment of arthritis and rheumatoid arthritis. Furthermore, capsaicin patches and ketoprofen patches are also gaining traction in the market owing to their increased adoption as well as demand for alternative therapies.
Based on distribution channel, the non-opioid pain patches market is segmented into hospitals, online pharmacies, and drug stores. Majority of these products are available as OTC products and can be purchased from distribution channels as per the physician’s recommendation. These patches are easily available; however, distribution channels vary depending upon the usage.
Hospitals held a considerable market share owing to frequent patient visits/admissions for pain management, especially by patients suffering from musculoskeletal disorders and other diseases that cause acute and chronic pain. Long-term use of painkillers usually bring about an additional risk of medication-related adverse effects. Thus, physicians usually prescribe patches instead of oral drugs.
The sale of drugs and medical devices has witnessed a surge following the emergence of online pharmacies. The availability of these products at online pharmacies facilitates individuals to purchase them in order to alleviate acute and chronic pain. As these can be purchased without a prescription, users find it more convenient to purchase them from online pharmacies leading to the market growth.
OTC products and prescription medicines are mostly purchased from drug stores. Prominent drug stores across the U.S. stock products as a large percentage of population suffers from pain-related disorders. As the nation is facing an opioid epidemic, many users are shifting to these patches to manage pain, boosting the market.
In 2018, North America accounted for the largest revenue share of the market. Increasing incidence of pain and pain-related disorders coupled with the escalating opioid epidemic in the U.S. are among factors driving the market in this region. According to American Chiropractic Association, Americans spend at least USD 50 billion on the treatment of back pain. Back pain is the second most common ailment for which patients visit doctors, and it is largely outnumbered by upper respiratory infections. Thus, therapies to combat pain need to be developed in this region. As these patches alleviate pain, reduce the risk of adverse effects, and have a lesser chance of being misused & leading to addiction, their demand is expected to be high in this region.
The Asia Pacific region is witnessing a lucrative growth in the pharmaceutical and medical device industries. The region exhibited the highest CAGR during the forecast period. With a sharp rise in lifestyle-related disorders and sedentary lifestyle, there has been a rise in the number of patients suffering from chronic and acute pain. With major developers making efforts to ensure the availability of non-opioid patches in the region, Asia Pacific is likely to witness significant growth over the forecast period.
Latin America has also been witnessing immense burden with respect to back pain and other musculoskeletal disorders, and this has been adding to healthcare expenditures of the nations in the region. Incremental rise in the number of patients and increasing product cognizance & adoption has also been accelerating market growth in the region.
The market is highly fragmented as various companies are engaged in their development to aid a large global population suffering from chronic pain.
Various market players use a wide range of technologies to develop products that facilitate effective and prolonged drug release to increase consumer base and product penetration. In addition, the market is very competitive in nature with intense competition between existing players and new entrants.
In addition, key participants are engaged in mergers and acquisitions to expand their existing product portfolios. For instance, in July 2013, Acorda Therapeutics announced the acquisition of two products from NeurogesX, Inc. to further strengthen its neuropathic pain management product portfolio. The two acquired products include, Qutenza and Phase 3-Stage Product NP-1998 used for the treatment of Postherpetic Neuralgia and diabetic neuropathy, respectively.
Major market players are also engaged in collaborations with distribution companies to increase product penetration. For instance, in October 2014, Richmar, Inc. announced the distribution of LidoFlex Pain Relief Patch by two companies of the Scrip Companies group. The companies are suppliers of chiropractic products and physical therapy equipment & supplies. Some of the prominent players in the non-opioid pain patches market include:
Acorda Therapeutics
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Endo Pharmaceuticals, Inc.
Hisamitsu Pharmaceutical Co., Inc.
IBSA Institut Biochimque SA
Alkermes
Teikoku Seiyaku Co. Ltd.
Capsugel
Mylan N.V.
Report Attribute |
Details |
Market size value in 2020 |
USD 790.74 million |
Revenue forecast in 2026 |
USD 1,040 million |
Growth Rate |
CAGR of 4.6% from 2019 to 2026 |
Base year for estimation |
2018 |
Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Quantitative units |
Revenue in USD million and CAGR from 2019 to 2026 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Patch type, distribution channel, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Russia; Japan; China; India; South Korea; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Acorda Therapeutics; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Endo Pharmaceuticals, Inc.; Hisamitsu Pharmaceutical Co., Inc.; IBSA Institut Biochimque SA; Alkermes; Teikoku Seiyaku Co. Ltd.; Capsugel; Mylan N.V. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the industry trends in each of the sub segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global non-opioid pain patches market report on the basis of patch type, distribution channel, and region:
Patch Type (Revenue, USD Million, 2015 - 2026)
Lidocaine Patches
Diclofenac Patches
Methyl Salicylate Patches
Capsaicin Patches
Ketoprofen Patches
Distribution Channel Outlook (Revenue, USD Million, 2015 - 2026)
Hospitals
Online Pharmacies
Drug Stores
Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Russia
Asia Pacific
Japan
China
India
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
The Middle East and Africa
South Africa
Saudi Arabia
UAE
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.